-
2 months ago | 
onlinelibrary.wiley.com | Robert Dreicer |Michael Devitt |Matthew McCord |Prem P. Batchala
1 Introduction In the United States, prostate cancer is the most common non-cutaneous malignancy in males [1]. Distant metastasis is present in 4%–25% of prostate cancer patients [2], but intracranial metastases are rare (0.6%–2.9%) and involve the meninges (66%) more commonly than the parenchyma (33%) [3]. Advanced prostate cancer (aPC) with small cell and neuroendocrine-transformed types are more frequently associated with intraparenchymal brain metastases (BMETS) [4].
-
Oct 25, 2024 | 
jwatch.org | Robert Dreicer
Robert Dreicer, MD, MS, MACP, FASCO, reviewing Five-fraction SBRT was noninferior to standard radiotherapy for freedom from biochemical/clinical failure in patients with low- to intermediate-risk disease. Patients with low- to intermediate-risk prostate cancer have a number of potential management options including active surveillance (primarily for low-risk cancer) and surgery or radiotherapy with curative intent.
-
Oct 10, 2024 | 
jwatch.org | Robert Dreicer
-
Oct 8, 2024 | 
jwatch.org | Robert Dreicer
-
Oct 3, 2024 | 
jwatch.org | Robert Dreicer
Robert Dreicer, MD, MS, MACP, FASCO, reviewing Adjuvant pembrolizumab improved disease-free survival in patients with high-risk urothelial cancer. Patients with muscle-invasive urothelial cancer following optimal therapy with cisplatin-based neoadjuvant chemotherapy and cystectomy remain at high risk for systemic failure, and those who are not candidates for perioperative chemotherapy are at even higher risk.
-
Sep 30, 2024 | 
jwatch.org | Robert Dreicer
Robert Dreicer, MD, MS, MACP, FASCO, reviewing Adding perioperative durvalumab to neoadjuvant gemcitabine-cisplatin and radical cystectomy improved overall survival. Cisplatin-based neoadjuvant chemotherapy can modestly improve overall survival (OS) in patients with muscle-invasive bladder cancer undergoing radical cystectomy.
-
Sep 25, 2024 | 
jwatch.org | Robert Dreicer
CitationsMorris MJ et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial. Lancet 2024 Sep 15; [e-pub]. ( https://doi.org/10.1016/S0140-6736(24)01653-2)Mateo J and Zurita AJ. 177Lu-PSMA-617 for metastatic prostate cancer: Aiming for the right spot. 2024 Sep 13; [e-pub]. ( https://doi.org/10.1016/S0140-6736(24)01919-6)
-
Aug 26, 2024 | 
jwatch.org | Robert Dreicer
-
Aug 23, 2024 | 
onclive.com | Robert Dreicer
CommentaryVideoAugust 23, 2024Author(s):Robert Dreicer, MD, discusses his presentation from the 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
-
Jul 31, 2024 | 
onclive.com | Robert Dreicer
Robert Dreicer, MD, deputy director and director of solid tumor oncology in the Division of Hematology/Oncology, and professor of medicine and urology at the University of Virginia Cancer Center, discusses the complexities surrounding biochemical failure after radical prostatectomy in patients with prostate cancer. This condition, commonly indicated by a rise in prostate-specific antigen (PSA) levels post-surgery or radiation therapy, occurs in 30% to 40% of cases.
